20 (AIDX) Cash from Financing Activities (2025 - 2026)
20 (AIDX) posted Cash from Financing Activities of $4.5 million for Q1 2026, up 1610.55% on a QoQ basis from $262338.0 in Q1 2025, and up 1610.55% year-over-year from $262338.0 in Q1 2025.
20 (AIDX) Cash from Financing Activities (2025 - 2026) Analysis & Trends
20's Cash from Financing Activities history runs 2 years deep, the most recent figure standing at $4.5 million for Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | -25.00 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -26.93 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 21.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | 20 | 3.91 Mn | -313,912.28 | 62,884.00 | 4.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.49 Mn |
| Mar 31, 2026 | 4.49 Mn |
| Mar 31, 2025 | 262,338.00 |
| Mar 31, 2025 | 262,338.00 |